{
    "clinical_study": {
        "@rank": "112450", 
        "arm_group": [
            {
                "arm_group_label": "Experimental Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Experimental Eye drops 3.0 \u00b5g/mL QD both eyes on Day 1, 5-18"
            }, 
            {
                "arm_group_label": "Experimental Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Experimental Eye drops 10.0 \u00b5g/mL QD both eyes on Day 1, 5-18"
            }, 
            {
                "arm_group_label": "Experimental Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "Experimental Eye drop 30.0 \u00b5g/mL QD both eyes on day 1, 5-18"
            }, 
            {
                "arm_group_label": "Experimental Arm 4", 
                "arm_group_type": "Experimental", 
                "description": "Experimental Eye drop, 2 sequence crossover Cohort [1 dose; 1-30 \u00b5g/mL]to be determined and placebo"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matched placebo eye drops dosed in same manner as ONO-9054"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the safety and tolerability of 3 planned\n      doses of ONO-9054 in the eyes of adult male and female patients with ocular hypertension\n      (OHT) or mild open angle-glaucoma (OAG).\n\n      The secondary objectives are to evaluate Pharmacodynamics (PD) and to characterize the\n      pharmacokinetic (PK) profile of ONO-9054 and its metabolite in plasma and to compare its\n      tolerability following morning and evening dosing."
        }, 
        "brief_title": "Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma", 
        "condition": [
            "Ocular Hypertension (OHT)", 
            "Mild Open Angle-glaucoma (OAG)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects age 18-80 (inclusive) with confirmed diagnosis of OHT or OAG\n\n          -  Confirmed diagnosis of bilateral OHT or chronic open-angle glaucoma\n\n          -  Able to undergo washout of all ocular drugs\n\n          -  An IOP \u2265 22mmHg at 8:00 AM and \u2265 21 mmHg at 10:00 AM in at least one eye; but \u2264 35\n             mmHg at all time points in both eyes on Day -2 and Day -1\n\n          -  Central corneal thickness 500-600 \u00b5m at screening in both eyes\n\n          -  BCVA 20/100 or better in both eyes\n\n        Exclusion Criteria:\n\n          -  Any history of severe ocular trauma in either eye at any time\n\n          -  Any history of previous intraocular or ocular laser surgery within the past 3 months\n             or any refractive surgery procedure within the past 6 months of screening visit in\n             the study eye(s)\n\n          -  Cataracts that prevent observation of the fundus in either eye"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670266", 
            "org_study_id": "ONO-9054IOU002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Experimental Arm 1", 
                    "Experimental Arm 2", 
                    "Experimental Arm 3", 
                    "Experimental Arm 4"
                ], 
                "intervention_name": "ONO-9054", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Experimental Arm 4", 
                    "Placebo Arm"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ONO-9054", 
            "ocular hypertension", 
            "OHT", 
            "Open angle-glaucoma", 
            "OAG", 
            "Glaucoma", 
            "Eye diseases"
        ], 
        "lastchanged_date": "May 31, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Costa Mesa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92626"
                    }, 
                    "name": "Costa Mesa Clinical Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newport Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92663"
                    }, 
                    "name": "Newport Beach (satellite site)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Ana", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92705"
                    }, 
                    "name": "Santa Ana (satellite site)"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Double-masked, Placebo-controlled, Dose-escalation Study and Double-masked, Two-sequence, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-9054 in Patients With Ocular Hypertension or Mild Open-Angle Glaucoma", 
        "overall_official": {
            "affiliation": "Ono Pharmaceutical Co. Ltd", 
            "last_name": "Ono Pharma USA, Inc.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Safety and tolerability of ONO-9054 will be measured using vital signs, ECGs, laboratory tests, ocular exams, physical examination and incidence/severity of adverse events over a dosing period of up to 14 days", 
            "measure": "Safety and tolerability of ONO-9054", 
            "safety_issue": "Yes", 
            "time_frame": "up to 14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670266"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The mean concentrations of ONO-9054 and its active metabolite will be measured in plasma in order to determine peak and trough levels over a dosing period of 14 days", 
                "measure": "Characterization of PK profiles", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days"
            }, 
            {
                "description": "The pharmacodynamic measurement will be intraocular pressure.  Relative changes with respect to baseline will be assessed after 14 days of administration under both AM and PM dosing conditions.", 
                "measure": "Evaluation of PD measurements", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days"
            }, 
            {
                "description": "Safety and tolerability of a single concentration will be evaluated by review of adverse events and any change from baseline in ocular symptoms  in a crossover arm in which the active drug is administered for 14 days under both AM and PM dosing conditions.", 
                "measure": "Comparison of safety, tolerability between once daily morning and once daily evening", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Ono Pharmaceutical Co. Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ono Pharma USA Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}